Generic Angiomax RTU Availability
Last updated on Apr 10, 2025.
See also: Generic Angiomax
Angiomax RTU is a brand name of bivalirudin, approved by the FDA in the following formulation(s):
ANGIOMAX RTU (bivalirudin - solution;intravenous)
-
Manufacturer: MAIA PHARMS INC
Approval date: July 25, 2019
Strength(s): 250MG/50ML (5MG/ML) [RLD]
Is there a generic version of Angiomax RTU available?
No. There is currently no therapeutically equivalent version of Angiomax RTU available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Angiomax RTU. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Ready-to-use bivalirudin compositions
Patent 11,903,993
Issued: February 20, 2024
Inventor(s): Sundaram; Srikanth
Assignee(s): MAIA PHARMACEUTICALS, INC. (Princeton, NJ)Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
Patent expiration dates:
- May 20, 2039✓
- May 20, 2039
-
Ready-to-use bivalirudin compositions
Patent 11,918,622
Issued: March 5, 2024
Inventor(s): Sundaram; Srikanth
Assignee(s): MAIA PHARMACEUTICALS, INC. (Princeton, NJ)Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
Patent expiration dates:
- May 20, 2039✓
- May 20, 2039
-
Ready-to-use bivalirudin compositions
Patent 11,992,514
Issued: May 28, 2024
Inventor(s): Sundaram; Srikanth
Assignee(s): MAIA PHARMACEUTICALS, INC. (Princeton, NJ)Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.
Patent expiration dates:
- May 20, 2039✓
- May 20, 2039
More about Angiomax RTU (bivalirudin)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: thrombin inhibitors
- Breastfeeding
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.